Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has maintained an Outperform rating on Kiniksa Pharmaceuticals (NASDAQ:KNSA) and increased the price target from $23 to $25.
January 02, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst reaffirms Outperform rating on Kiniksa Pharmaceuticals and raises price target to $25, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically signals a bullish outlook on the stock, suggesting that the analyst expects the stock to perform well in the near term. Investors often view such updates as a positive sign and may increase their buying activity, potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100